Marina N. Makarova, Director of Research and manufacturing company «Home оf Pharmacy» and Valery G. Makarov, Scientific Director of the organization, attended the XVIII Congress ‘Drug Development and Registration’, (February 26-27, 2025 in Moscow).
Marina Makarova made a presentations entitled “Relevance of test systems used for preclinical studies of medicines” and “Types of GLP inspections and who is responsible for it”.
On May 14-16, 2024, the Head of the Department of Technology, Kinetics and Analysis of Medicinal Products Marina Karlina made a report “DEVELOPMENT OF A MEDICINE AND TARGET QUALITY PROFILE” at the The 7th St. Petersburg Medical Innovation Forum.
RMC «HOME OF PHARMACY» received a license for the circulation of narcotic drugs, psychotropic substances and their precursors, the cultivation of drug-containing plants № ЛО17-01149-47/00669268.
Specialists of «RMC «HOME OF PHARMACY» took part in the IV GLP-PLANET conference, in which representatives of the regulator, leading specialists of testing facilities and pharmaceutical companies discussed the most important issues arising during preclinical studies. GLP-PLANET annually brings together leading international and Russian experts in the pharmaceutical industry, government representatives, managers and specialists of science centers and pharmaceutical companies, representatives of professional associations and communities, experts in the field of Quality Management System and Good Laboratory Practice (GLP).
We also review the work of our colleagues, who have returned from “Actual Problems of Biomedicine – 2023” Conferences in St. Petersburg where they presented the results of their research.
A monograph “Recommendations for conducting necropsy of laboratory animals” has been published. Full text is available only in Russian.
Scientific Director of RMC «HOME OF PHARMACY» Valery Makarov took part on-line in the work of the VII All-Russian GMP Conference.
RMC «HOME OF PHARMACY» is registered in the Chestny Znak system. Acceptance of drugs registered in the Russian Federation can be carried out by direct or reverse acceptance, at the discretion of the Sponsor. Withdrawal from circulation of labeled medicinal products for research is carried out using 552 schemes (withdrawal from circulation) with code 9 (for the purposes of clinical trials) or with code 13 (write-off without transfer for destruction).
On June 30 – July 01, 2022, staff of «RMC «HOME OF PHARMACY» took part in the III GLP-PLANET conference, in which representatives of the regulator, leading specialists of testing facilities and pharmaceutical companies discussed the most important issues arising during preclinical studies. The results of the conference can be found on the website.
